Distribution of pathogens causing nosocomial infection in patients with bronchial asthma.

This study aimed to analyze nosocomial respiratory infection (NRI) in patients with bronchial asthma. Among the clinical data of 575 asthmatic patients that was collected and analyzed, 52 were diagnosed with NRI. The most common gram-positive bacterial species was Streptococcus pneumoniae, which was detected in 8 patients, whereas the predominant Gram-negative bacteria included Haemophilus influenzae (11 patients), Moraxella catarrhalis (8 patients), and Escherichia coli (7 patients). The simultaneous detection of all strains was predominant in patients older than 65 years of age, whereas the detection rates of S. pneumoniae, H. influenzae, E. coli, and M. catarrhalis were predominant in patients younger than 65 years old. The differences in the detection rates were not significant between the male and female groups. From this study, we can conclude that S. pneumoniae, H. influenzae, E. coli, and M. catarrhalis are common NRI-causing pathogens, and bacterial infection is the main risk factor for NRI in asthmatic patients.

N1-guanyl-1,7-diaminoheptane enhances the chemosensitivity of NSCLC cells to cetuximab through inhibition of eukaryotic translation initiation factor 5A2 activation.

OBJECTIVE: N1-guanyl-1, 7-diaminoheptane (GC7), an inhibitor of deoxyhypusine synthase has been shown to exhibit significant anti-cancer activity. However, the biological role of eukaryotic translation initiation factor 5A2 activation (EIF5A2) and GC7 on drug resistance in non-small cell lung cancer (NSCLC) has not been investigated. In this study, we aimed to investigate the therapeutic effect of GC7 combined with cetuximab in NSCLC therapy. MATERIALS AND METHODS: The current study used cell viability assays, EdU incorporation assays, and western blot to detect that the GC7 exhibited synergistic cytotoxicity with cetuximab in NSCLC. RESULTS: CCK-8 assays showed that combined treatment with GC7 and cetuximab significantly inhibited the viabilities in three NSCLC cell lines. In addition, EdU incorporation assays also indicated that GC7 co-treatment remarkably enhanced the cetuximab sensitivity in NSCLC cells. Nevertheless, down-regulation of EIF5A2 diminished the regulatory role of GC7 in cetuximab cytotoxicity. Western blot showed that transfection of EIF5A2 siRNA significantly suppressed the protein expression of EIF5A2 in NSCLC cells. CONCLUSIONS: These findings demonstrate that combined treatment with GC7 could enhance cetuximab sensitivity by inhibiting EIF5A2 in NSCLC cells, implying the potential clinical application of GC7 in cetuximab-based chemotherapy for NSCLC patients.